**Core Concept**
Bleomycin is a chemotherapeutic agent that induces pulmonary toxicity, leading to damage of lung tissue. This toxicity is characterized by the destruction of a specific type of pneumocyte, which is crucial for gas exchange in the lungs.

**Why the Correct Answer is Right**
Bleomycin toxicity primarily affects Type I pneumocytes, which are responsible for the majority of gas exchange in the lungs. The drug causes these cells to undergo apoptosis, leading to a loss of lung function and potentially resulting in pulmonary fibrosis. This is due to the action of bleomycin on the enzyme bleomycin hydrolase, which is present in Type I pneumocytes but not in Type II pneumocytes. The subsequent release of reactive oxygen species and activation of various signaling pathways ultimately lead to the destruction of these cells.

**Why Each Wrong Option is Incorrect**
* **Option A:** Endothelial cells are not the primary target of bleomycin toxicity. While endothelial damage can occur in response to bleomycin-induced damage to pneumocytes, it is not the primary mechanism of toxicity.
* **Option C:** Type II pneumocytes are responsible for producing surfactant and have a role in the repair of damaged lung tissue. They are not the primary target of bleomycin toxicity, although they may be affected indirectly as a result of the damage to Type I pneumocytes.
* **Option D:** Alveolar macrophages play a role in the clearance of inhaled particles and pathogens, but they are not the primary target of bleomycin toxicity.

**Clinical Pearl / High-Yield Fact**
Bleomycin toxicity is a significant concern in patients receiving this chemotherapeutic agent, particularly those with pre-existing lung disease. The use of pulmonary function tests and chest imaging studies can help monitor for signs of toxicity, and dose adjustments or cessation of the drug may be necessary to prevent further damage.

✓ Correct Answer: B. Type I pneumocytes